Following the mandate given by the European Commission to the SCCS in the context of the safety assessment of substances with potential endocrine disrupting properties, the Scientific Committee has just published its Scientific advice on Homosalate (UV-Filter). It was adopted by written procedure on 2 December 2021 in its final version and is not open for comments.
Background
Homosalate (CAS No.118-56-9, EC No.204-260-8) has been evaluated for its safety by the SCCP in 2007 (SCCP/1086/07) and is currently regulated as a UV-filter in sunscreen products in a concentration up to 10 % (Annex VI/3).
On 24-25 June 2021, the SCCS adopted an Opinion (SCCS/1622/20) concluding that Homosalate could not be considered safe at concentrations of up to 10%. According to the SCCS’s Opinion, the use of Homosalate is safe for the consumer up to a maximum concentration of 0.5% in the final product.
On 30 July 2021, in order to ensure broad availability of UV-filters and consequently adequate sun protection for consumers, industry submitted a re-calculation of the Margin of Safety (MoS) based only on the use of Homosalate in face products (face cream and pump-spray products).
For an exhaustive background information, see the articles
• Homosalate: Final Opinion of the SCCS, CosmeticOBS, 5 July 2021
• Butylparaben, Homosalate: requests for SCCS Opinions, CosmetiOBS, 19 October 2021
Opinion
1. In light of the information provided and taking under consideration the concerns related to potential endocrine disrupting properties of Homosalate, does the SCCS consider Homosalate safe when used as a UV-filter in face products (face cream …
